Pasteurellaceae vaccines
AssigneeETH Zurich
InventorsMarkus Aebi, Flavio Schwarz, Andreas Naegeli
Life of this patent
Estimating the term…
Abstract
The present invention relates to an N-glycosylated protein for treating and/or preventing bacterial Pasteurellaceae infection in a mammal or bird, wherein the protein is a Pasteurellaceae protein, a functional fragment or derivative thereof having at least one glycosylated N-X-S/T consensus sequence. In addition, the present invention is directed to corresponding pharmaceutical compositions for treating and/or protecting mammals or birds having or being prone to develop a bacterial Pasteurellaceae infection. Furthermore, the invention describes methods for producing said N-glycosylated proteins.
Claims14
1-14. (canceled)
N-glycosylated protein for the manufacture of a medicament for treating and/or preventing bacterial Pasteurellaceae infection in a mammal or bird, wherein the protein is a Pasteurellaceae protein, a functional fragment or derivative thereof having at least one glycosylated N-X-S/T consensus sequence, wherein X is not Pro, and wherein the Pasteurellaceae protein, functional fragment or derivative thereof is
- (1) autotransporter adhesin [ataC] A. pleuropneumoniae serotype 7 (strain AP76) (accession no. B3GX20_ACTP7;
- SEQ ID NO:
- 1), or
- (2) AT family autotransporter/adhesin [COK—1394] Mannheimia haemolytica serotype A2 str. BOVINE (accession number E2P8A5_PASHA;
- SEQ ID NO:
- 13), or
- (3) a functional fragment or derivative having at least 40, preferably at least 50, more preferably at least 70, most preferably at least 80% amino acid sequence identity to (1) or (2).
Dependencies are inferred from the claim text.